Jin Yang Pharmaceutical Co. Ltd Net Assets

Latest as of June 2026: ₩162.16 Billion KRW ≈ $109.89 Million USD

Jin Yang Pharmaceutical Co. Ltd net assets. Based on the latest financial reports, Jin Yang Pharmaceutical Co. Ltd (007370) has net assets worth ₩162.16 Billion KRW (≈ $109.89 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩274.42 Billion ≈ $185.97 Million USD) and total liabilities (₩112.26 Billion ≈ $76.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 007370 net assets growth trend to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩162.16 Billion
% of Total Assets	59.09%
Annual Growth Rate	9.08%
5-Year Change	144.74%
10-Year Change	225.27%
Growth Volatility	18.65

Net Assets of Jin Yang Pharmaceutical Co. Ltd (2014–2025)

Net assets of Jin Yang Pharmaceutical Co. Ltd from 2014 to 2025. This chart illustrates how Jin Yang Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Jin Yang Pharmaceutical Co. Ltd to measure how much of total assets are equity-financed.

Annual Net Assets for Jin Yang Pharmaceutical Co. Ltd (2014–2025)

The table below shows the annual net assets of Jin Yang Pharmaceutical Co. Ltd from 2014 to 2025. For live market cap and overall valuation, see 007370 stock market capitalisation.

Year	Net Assets	Change
2025-12-31	₩159.86 Billion ≈ $108.33 Million	+33.35%
2024-12-31	₩119.88 Billion ≈ $81.24 Million	+33.82%
2023-12-31	₩89.58 Billion ≈ $60.71 Million	+15.48%
2022-12-31	₩77.58 Billion ≈ $52.57 Million	+18.77%
2021-12-31	₩65.32 Billion ≈ $44.26 Million	+41.04%
2020-12-31	₩46.31 Billion ≈ $31.38 Million	+6.06%
2019-12-31	₩43.67 Billion ≈ $29.59 Million	+3.85%
2018-12-31	₩42.05 Billion ≈ $28.50 Million	-0.79%
2017-12-31	₩42.38 Billion ≈ $28.72 Million	-13.77%
2016-12-31	₩49.15 Billion ≈ $33.31 Million	-16.95%
2015-12-31	₩59.18 Billion ≈ $40.10 Million	-3.75%
2014-12-31	₩61.48 Billion ≈ $41.66 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jin Yang Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 137.3% over the analyzed period, indicating profitable operations and earnings retention.

Jin Yang Pharmaceutical Co. Ltd Net Assets Breakdown (December 2025)

Jin Yang Pharmaceutical Co. Ltd net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Retained Earnings	₩109.57 Billion	68.54%
Other Components	₩50.29 Billion	31.46%
Total Equity	₩159.86 Billion	100.00%

Jin Yang Pharmaceutical Co. Ltd Competitors by Market Cap

The table below lists competitors of Jin Yang Pharmaceutical Co. Ltd ranked by their market capitalization.

Company	Market Cap
Steady Safe TBK PT JK:SAFE	$32.48 Million
NextNRG Inc. NASDAQ:NXXT	$32.48 Million
Tocvan Ventures Corp F:TV3	$32.49 Million
Impresa - Sociedade Gestora de Participações Sociais S.A LS:IPR	$32.51 Million
Reckon Ltd AU:RKN	$32.47 Million
Phoenix Materials Co. Ltd KQ:050090	$32.46 Million
Sharps Technology Inc NASDAQ:STSS	$32.46 Million
Aarey Drugs & Pharmaceuticals Limited NSE:AAREYDRUGS	$32.43 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jin Yang Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 119,877,794,630 to 159,856,760,000, a change of 39,978,965,370 (33.3%).
Net income of 22,286,848,620 contributed positively to equity growth.
Dividend payments of 1,714,017,300 reduced retained earnings.
New share issuances of 3,123,716,210 increased equity.
Other factors increased equity by 16,282,417,840.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩22.29 Billion	+13.94%
Dividends Paid	₩1.71 Billion	-1.07%
Share Issuances	₩3.12 Billion	+1.95%
Other Changes	₩16.28 Billion	+10.19%
Total Change	₩-	33.35%

Book Value vs Market Value Analysis

This analysis compares Jin Yang Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.30x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 0.77x to 0.30x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩4396.94	₩3390.00	x
2017-12-31	₩3791.68	₩3390.00	x
2018-12-31	₩3761.85	₩3390.00	x
2019-12-31	₩3906.64	₩3390.00	x
2020-12-31	₩4143.24	₩3390.00	x
2021-12-31	₩5843.72	₩3390.00	x
2022-12-31	₩7199.14	₩3390.00	x
2023-12-31	₩8313.54	₩3390.00	x
2024-12-31	₩10490.95	₩3390.00	x
2025-12-31	₩11309.62	₩3390.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jin Yang Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 13.94%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 18.47%
• Asset Turnover: 0.45x
• Equity Multiplier: 1.68x
Recent ROE (13.94%) is above the historical average (5.83%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	6.53%	8.87%	0.59x	1.25x	₩-2.14 Billion
2015	-1.70%	-2.50%	0.46x	1.47x	₩-6.92 Billion
2016	-18.51%	-25.18%	0.47x	1.56x	₩-14.01 Billion
2017	-13.61%	-13.28%	0.59x	1.74x	₩-10.01 Billion
2018	2.22%	1.99%	0.67x	1.67x	₩-3.27 Billion
2019	3.77%	3.48%	0.69x	1.56x	₩-2.72 Billion
2020	7.94%	7.53%	0.72x	1.47x	₩-954.47 Million
2021	14.60%	15.18%	0.64x	1.51x	₩3.01 Billion
2022	15.87%	16.14%	0.67x	1.48x	₩4.55 Billion
2023	14.13%	13.45%	0.78x	1.34x	₩3.70 Billion
2024	24.77%	26.20%	0.50x	1.90x	₩17.71 Billion
2025	13.94%	18.47%	0.45x	1.68x	₩6.30 Billion

Industry Comparison

This section compares Jin Yang Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $490,498,627,337
Average return on equity (ROE) among peers: 5.97%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jin Yang Pharmaceutical Co. Ltd (007370)	₩162.16 Billion	6.53%	0.69x	$32.47 Million
Dongwha Pharm.Co.Ltd (000020)	$229.62 Billion	7.70%	0.48x	$98.05 Million
Yuhan Corp. (000100)	$1.12 Trillion	8.27%	0.18x	$3.84 Billion
Yuhan Corp Preferred (000105)	$2.36 Trillion	8.22%	0.36x	$45.29 Million
Yuyu Pharma (000220)	$82.83 Billion	5.48%	0.47x	$40.03 Million
Yuyu Pharma Inc (000225)	$78.29 Billion	7.52%	0.42x	$13.08 Million
Yuyu Pharma Inc (000227)	$78.29 Billion	7.52%	0.42x	$32.56 Million
Ildong Holdings Co Ltd (000230)	$349.98 Billion	5.99%	1.02x	$43.17 Million
Samil Pharm (000520)	$70.03 Billion	11.32%	0.65x	$108.19 Million
Donga Socio Holdings (000640)	$306.84 Billion	8.70%	1.30x	$379.59 Million
Jw Pharmac (001060)	$230.09 Billion	-10.98%	1.49x	$349.95 Million

About Jin Yang Pharmaceutical Co. Ltd

KQ:007370 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$32.47 Million

₩47.92 Billion KRW

Market Cap Rank

#23288 Global

#1594 in Korea

Share Price

₩3390.00

Change (1 day)

-2.02%

52-Week Range

₩3390.00 - ₩5470.00

All Time High

₩9262.22